2seventy bio, Inc. is a US-based company that specializes in researching and developing cell and gene therapies for cancer treatments. They have a range of products in the pipeline, including idecabtagene vicleucel and bb21217, which are aimed at treating multiple myeloma. In addition, the company has a collaboration agreement with Bristol-Myers Squibb Company and is based in Cambridge, Massachusetts.